Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of pathologies ranging
from uncomplicated hepatic fat accumulation to a state of lobular inflammation and …

Background As the prevalence of hepatitis steatosis (HS) increases, the prevalence of HS
among those with chronic hepatitis B (CHB) may also be increasing but data on the effect of …

Fibroblast growth factor (FGF) 21 is one of the FGF members with special endocrine
properties. In the last twenty years, it has attracted intense research and development for its …

Background Metabolic dysfunction-associated fatty liver disease (MAFLD) is a novel
proposed concept that is being recognized worldwide. Both chronic hepatitis B (CHB) and …

Diabetes mellitus (DM) is a common chronic disease affecting humans globally. During the
last few years, the incidence of diabetes has increased and has received more attention. In …

Background The association between hepatic steatosis (HS) and chronic hepatitis B (CHB)
remains controversial. We performed a systematic review and meta-analysis to investigate …

Background The global prevalence of chronic hepatitis B is more than 300 million people,
and in Denmark, 17,000 people are estimated to have chronic hepatitis B. Untreated …

Background Serum mac-2-binding protein glycosylation isomer (M2BPGi) is a novel marker
for liver fibrosis assessment in patients with different liver diseases. For chronic hepatitis B …

目的探讨应用恩替卡韦联合甘草酸二铵治疗慢性乙型肝炎(CHB) 患者的短期效果和血清细胞
因子水平变化. 方法2019 年1 月~ 2020 年2 月我院收治的98 例CHB 患者, 被随机分为对照组49 …

Background and aims Chronic hepatitis B (CHB) and non-alcoholic fatty liver disease
(NAFLD) are leading causes of liver-related morbidity and mortality. The interaction between …